Opendata, web and dolomites

SN-marker SIGNED

Secretoneurin (SN): the first blood biomarker to accurately stratify mortality risk in patients with cardiac arrhythmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SN-marker project word cloud

Explore the words cloud of the SN-marker project. It provides you a very rough idea of what is the project "SN-marker" about.

alone    sales    echocardiogram    hf    select    blood    patient    defibrillator    market    biomarkers    half    secretoneurin    2020    q3    implantable    24    accurately    provides    accurate    normal    difficult    134m    trl6    pinpoint    biomarker    ejection    vitro    time    cardiovascular    months    deaths    activated    mechanisms    death    killer    first    capacity    kit    frequent    categories    diagnostic    elisa    levels    keeping    lt    cardiologists    worldwide    surgery    51    cardiac    least    2018    rightly    added    cardinor    never    heart    ecg    platforms    lvef    prognostic    rights    10    caused    cvd    threatening    arrhythmia    67    35    info    correlation    ventricular    unmatched    chain    stratify    icd    risk    survival    helps    patients    data    disease    detect    ivd    ipr    victims    scd    cardioverter    diagnosis    eligible    34    unknowingly    icds    20k    saved    left    sn    overtreatment    arrhythmias    decision    urgently    sudden    prescribe    reached    life    diverted    assay    ventricle   

Project "SN-marker" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. At least half of CVD deaths is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival, being more frequent and carrying greater risk in heart failure (HF) patients. When managing HF patients, cardiologists currently prescribe an ECG (which may detect an arrhythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.34 B€ overtreatment cost/year in the EU alone. Cardiologists urgently need an accurate biomarker that helps to better stratify patients’ risk for life-threatening arrhythmia. Existing cardiac biomarkers do not provide that info, keeping under or overtreatment. CardiNor has IPR rights and is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a new biomarker that provides unmatched insight into the mechanisms of arrhythmia, with a prognostic capacity to accurately stratify the patients into risk categories. With SN data, cardiologists will be able to rightly pinpoint high-risk patients and select those patients to ICD surgery. For every 10% of ICD-eligible patients that are diverted from surgery more than 134M€ are saved every year. First sales will be in 2020 as an ELISA kit and over time added to other IVD platforms to increase exploitation potential. CardiNor and its value chain partners have been working together on the SN assay for 24 months, having reached TRL6 in Q3 2018.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SN-MARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SN-MARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More